People at risk for developing the clinical symptoms of Alzheimer’s disease (AD) are a critical population for testing new potential therapeutics, as the ability to intervene effectively in the disease process may be greatest before clinical onset. However, the optimal timing for intervention and sensitive indicators of therapeutic response in preclinical AD remain to be elucidated. These gaps in scientific knowledge hinder efforts to design efficient clinical trials that can evaluate potential therapeutics rapidly and effectively.
from Dementia Big http://ift.tt/1ZlFbMn
via Stopping Dementia
from WordPress http://ift.tt/1WdBvyu
via alcoholic dementia
http://ift.tt/1ZlIdQv
No comments:
Post a Comment